Cure8 research brief
The oral microbiome can influence gut microbes and inflammation; understanding this link could lead to new diagnostic markers (saliva) or combined dental–gastroenterology care approaches relevant to people with IBD.
Researchers studying the microbiome or immune mechanisms, gastroenterologists and dentists managing patients with IBD and periodontitis, and adult patients interested in oral–gut health links.
The review searched major databases through May 2026 and included 34 recent in vivo studies focusing on adult populations.
Several oral taxa—Porphyromonas gingivalis, Fusobacterium nucleatum, and Aggregatibacter actinomycetemcomitans—are highlighted as able to colonize the gut or alter its microbiota in ways associated with increased intestinal inflammation, potentially via Th17-mediated immune responses.
The authors note salivary microbial profiles were associated with IBD status in the included studies and suggest that future work could explore salivary markers and multidisciplinary care linking dental and gastroenterological management.
This is a scoping review of recent in vivo studies (34 articles) summarized in the journal Microorganisms; it highlights associations and proposed mechanisms but does not establish clinical diagnostic tests or therapies yet.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.
Environmental pollutants are increasingly linked to Crohn's disease risk, especially when exposures occur in early life. Understanding these links may help explain rising IBD rates and guide future prevention research.
Fibrosis and stricturing are key problems in Crohn’s disease with limited therapies; this study identifies a microbiota–bile acid–GPBAR1 pathway by which a specific probiotic mix reduced inflammation and fibrosis in...
